Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer
Latest Information Update: 09 May 2022
At a glance
- Drugs Cabozantinib (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CaboMAb
- 01 Jun 2021 Results published in the Oncologist
- 29 Jan 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Results from a cohort of patients with MET amplification detected in blood presented at the 54th Annual Meeting of the American Society of Clinical Oncology.